Related Experiment Video

Updated: May 9, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Triptolide inhibits the multidrug resistance in prostate cancer cells via the downregulation of MDR1 expression

Q Guo, X X Nan, J R Yang

    Neoplasma
    |August 3, 2013
    PubMed

    Insights

    Triptolide (TPL) effectively inhibits prostate cancer cell growth and induces apoptosis. It also re-sensitizes multidrug-resistant (MDR) prostate cancer cells to chemotherapy by downregulating MDR1 expression.

    Area of Science:

    • Pharmacology
    • Cancer Biology
    • Molecular Oncology

    Background:

    • Triptolide (TPL), a compound from Tripterygium wilfordii, shows anti-tumor properties.
    • The efficacy of TPL against prostate cancer and its ability to overcome multidrug resistance (MDR) remain underexplored.

    Purpose of the Study:

    • To investigate the effects of TPL on prostate cancer cell proliferation, cell cycle, and apoptosis.
    • To determine if TPL can overcome adriamycin (ADM) resistance in prostate cancer cells.
    • To elucidate the mechanism by which TPL affects multidrug resistance (MDR).

    Main Methods:

    • Utilized DU145 prostate cancer cell line and an adriamycin (ADM)-resistant subline (DU145/ADM).
    • Assessed TPL's impact on cell proliferation, cell cycle arrest, and apoptosis.
    • Quantified changes in key apoptosis-related proteins (Bcl-2, Fas, Bax) and cell cycle regulators (Cyclin D1).
    • Evaluated TPL's effect on ADM sensitivity and MDR1 expression at both mRNA and protein levels.

    Main Results:

    • TPL inhibited DU145 cell proliferation and induced cell cycle arrest and apoptosis in a dose- and time-dependent manner.
    • TPL modulated apoptosis-related proteins, decreasing Bcl-2 and increasing Fas and Bax.
    • TPL restored sensitivity of DU145/ADM cells to ADM and downregulated MDR1 expression.

    Conclusions:

    • TPL exhibits significant anti-prostate cancer activity and induces apoptosis.
    • TPL effectively overcomes multidrug resistance (MDR) in prostate cancer cells by downregulating MDR1.
    • TPL represents a potential therapeutic agent for prostate cancer, particularly for chemoresistant forms.

    More Related Videos

    Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment10:59

    Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

    Published on: November 23, 2017

    MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)08:30

    MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)

    Published on: May 16, 2012

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Drugs that Stabilize Microtubules01:15

    Drugs that Stabilize Microtubules

    Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
    Carrier-Mediated Transport01:06

    Carrier-Mediated Transport

    Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
    Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
    Drugs that Destabilize Microtubules01:10

    Drugs that Destabilize Microtubules

    Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...